73 employees
Nuvalent is a biotechnology company that develops targeted therapies for clinically proven kinase targets in cancer.
2017
$135M
from 4 investors over 4 rounds
Nuvalent, Inc. raised $135M on May 11, 2021
Investors: Logos Global Management, LP, Driehaus Capital Management LLC, Viking Global Investors and Wellington Management